Podcast description: rapamycin, aging biology and the Dog Aging Project with Dr. Matt Kaeberlein
In this described episode, host Nicole Doran speaks with aging biologist Dr. Matt Kaeberlein about rapamycin, an mTOR inhibitor that has extended lifespan in animals, and about the Dog Aging Project, a large study testing rapamycin in companion dogs. [1]
Automatic summary · not editorially reviewed
The key findings
The description says rapamycin is an mTOR inhibitor discovered on Easter Island and one of the most reproducible interventions shown to extend lifespan in animals. [1]
The description presents the Dog Aging Project as a large scale study testing rapamycin in companion dogs. [1]
The description says the episode covers early human research on Alzheimer's risk and immune function and how Optispan is building longevity focused diagnostics and clinical care. [1]
The source at a glance
- Study type / format
- Video description of a podcast interview episode
- Population / context
- Companion dogs in the described Dog Aging Project and, as discussed topics, humans in early research and clinical practice
- Summary based on
- Creator description
- Original publication
- March 10, 2026
Rapamycin and mTOR in animal aging research
According to the description, Dr. Kaeberlein shares decades of research on rapamycin, an mTOR inhibitor originally discovered on Easter Island. The description calls it one of the most reproducible interventions shown to extend lifespan in animals. It also says the conversation covers how rapamycin interacts with nutrient sensing, autophagy and chronic inflammation, and why targeting these biological pathways may influence many age related diseases at once. These are described topics of the episode, not results of a new human trial.
Supporting source [1]
Dog Aging Project and early human signals
The description presents the Dog Aging Project as a large scale study testing rapamycin in companion dogs, and asks what studying companion dogs can teach us about human longevity. It also mentions early human research related to vaccine response, Alzheimer's risk and post viral conditions, and lists metformin, SGLT2 inhibitors and other compounds being explored in aging research. The description does not report sample sizes, follow-up times or results for these items.
Supporting source [1]
Healthspan medicine and translating longevity science
The description says the episode explores the emerging field of healthspan medicine and how Dr. Kaeberlein's company Optispan is working to translate aging science into real clinical practice, including longevity focused diagnostics and clinical care. It also names the challenges of translating longevity science into real world medicine and lifestyle factors that still matter most for long term healthspan. The description frames these as discussion topics, not as validated treatments or proven human lifespan benefits.
Supporting source [1]
How to interpret this
This is based only on the supplied video description; the video and transcript were not reviewed. The description names topics and questions but reports no study designs, sample sizes, follow-up times or results, so no effect of rapamycin or other compounds in humans can be judged from it.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
The Healthspan Collective · youtube.com · March 10, 2026